Videos

KOMET-007 data spotlight ziftomenib combos in newly diagnosed NPM1/KMT2A AML, detailing dosing, sequencing, and maintenance with 7+3 or aza/ven.

Young women with lung cancer face stigma, misdiagnosis, trial underrepresentation, and missed fertility support—clinical gaps that delay care and worsen long-term outcomes.

Andrew Spencer, MBBS, discusses how the inMMyCar trial is finding promise for in vivo CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Susan Bal, MD, discusses outcomes with arlo-cel, a GPRC5D-targeted CAR T product in relapsed/refractory multiple myeloma.

Johannes Schetelig, MD, MSc, discusses the importance of preventing life-threatening infections in light of research showing high nonrelapse mortality with PTCy.

Benjamin Herzberg, MD, highlights ASCO 2026's most exciting KRAS data, sequencing strategies, and emerging therapies for KRAS-mutant lung cancer.

Johannes Schetelig, MD, MSc, discusses findings on graft-vs-host disease prophylaxis in unrelated donor allogeneic stem cell transplants.

Erika Hamilton, MD, reviews the manageable safety profile of tucatinib plus HP maintenance therapy in HER2+ metastatic breast cancer from HER2CLIMB-05.

Dr Ajaz Khan of City of Hope shares key ASCO 2026 takeaways, including giredestrant, selpercatinib, ivonescimab, and the rise of ctDNA and AI in oncology.

Experts discuss their ASCO presentations on 3 rare disease states: uveal melanoma, mucosal melanoma, and Merkel cell carcinoma.

The panel discusses first-line treatment selection once a ROS1 fusion is confirmed in a treatment-naive patient.

The panel discusses how patients with ROS1-positive advanced NSCLC arrive in clinic through in-system diagnosis, second opinions, or new patient referrals and the detective work required to ensure complete molecular testing is available before treatment decisions.

ROS1 gene fusions occur in approximately 1% to 2% of advanced NSCLC cases, a small but clinically meaningful subset predominantly found in younger patients, women, light or never smokers, and those with non-squamous histology, most commonly adenocarcinoma.

ANK-101, an IL-12 anchored immunotherapy, is being studied with checkpoint blockade in patients with non–small cell lung cancer in a phase 1b trial.

With 4 ROS1-directed TKIs now in the mix, community oncologists need a clear framework for sequencing and CNS considerations in this rare NSCLC subset.

ASCO 2026 highlights: KRAS signals, ADC‑immunotherapy momentum, and new TNBC/HER2 breakthroughs shaping next breast cancer trials.

Raj Singh, MD, discusses treatment gaps, emerging therapies, and the critical role of multidisciplinary care in managing brain tumors.

VIKTORIA-1 shows gedatolisib regimens double PFS and cut hyperglycemia vs alpelisib in PIK3CA-mutant HR+/HER2– breast cancer.

Living in food deserts links to aggressive ctDNA mutations and shorter metastatic breast cancer survival, with the starkest survival gaps seen in Black patients.

James W. Smithy, MD, MHS, discusses the key findings from a phase 2 trial of IO102-IO103 plus nivolumab/relatlimab in advanced melanoma.

Phase 2 study presented at ASCO 2026 shows fedratinib eases symptoms and shrinks spleens in rare MDS/MPN variants, offering a needed evidence-based option.

Allostatic load links chronic stress and social factors to early-onset cancer risk, offering a measurable path to improve risk models and prevention strategies.

Saad Z. Usmani, MD, MBA, shares guidance on improving tolerability of belantamab mafodotin based on clinical experience and findings from in the DREAMM-9 trial.

Saad Z. Usmani, MD, MBA, discusses the significance of the final analysis of the phase 3 CEPHEUS trial in newly diagnosed multiple myeloma.

ASCO 2026 data link chronic-stress allostatic load to higher early-onset cancer risk, suggesting new tools for screening beyond genetics.

Dr Tolaney discusses ASCENT-04 data, showing sacituzumab govitecan plus pembrolizumab improves PFS in 1L mTNBC across all Trop-2, tBRCA, and HER2 subgroups.

Michael C. Heinrich, MD, discusses the eventual goal of using velzatinib as an early-line treatment for gastrointestinal stromal tumors.

Mabel Mardones, MD, discusses findings from the phase 3 perservERA trial presented at ASCO 2026.

ASCO 2026 insights on 177Lu-PSMA-617 in mHSPC: safety, marrow and kidney monitoring, and what long-term MDS/AML risks may reveal.

Michael C. Heinrich, MD, discusses promising KIT mutation analyses from the phase 1b StrateGIST study in gastrointestinal stromal tumors.